{"pageContent": "Options to treat late-stage castration-resistant prostate cancer continued to increase in 2011, as three agents with different mechanisms of action prolonged life and a fourth reduced the morbidity of skeletal metastases. These outcomes contrasted with the heightened controversy generated by the recommendation against PSA screening and other early detection strategies.", "metaData": {"source": "High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact?\nhttps://pubmed.ncbi.nlm.nih.gov/17848666/"}}